Results 101 to 110 of about 6,775 (167)

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies. [PDF]

Int J Mol Sci
Meza K, Barrientos Risso C, Shah A, Romagnoli C, Sandoval J, Brauchle Y, Lyubimova A, Santos L, Goya Balaguer E, Barrientos J.   +9 more
europepmc   +1 more source

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study. [PDF]

Hemasphere
Cheah CY, Blombery P, Johnston A, Wight J, Lewis KL, Bennett R, Xie J, Vlachos S, Hunter SM, Gonzales J, Binks S, Seymour JF.   +11 more
europepmc   +1 more source

Comparison of Venetoclax-Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single-Center Real-World Experience. [PDF]

EJHaem
Heyman B, Choi M, Kipps TJ.
europepmc   +1 more source

Immune-mediated acute thrombocytopenia within 30 minutes of first obinutuzumab infusion. [PDF]

Blood Vessel Thromb Hemost
Al-Sayyad J, Lara-Martinez HR.
europepmc   +1 more source

Efficacy and safety of modified-dose obinutuzumab in the treatment of refractory membranous nephropathy. [PDF]

Front Immunol
Zhou J, Ai S, Zhang X, Wang X, Chen G, Wang Y.   +5 more
europepmc   +1 more source

The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis. [PDF]

Cureus
Timlin H, Koirala A, Geetha D, Azar A, Mener A.   +4 more
europepmc   +1 more source

Safety and Efficacy of Obinutuzumab in Treating Lupus Nephritis: A Systematic Review. [PDF]

Immun Inflamm Dis
Arif Z, Ali H, Siddiqui E, Naeem S, Amin MHJ.   +4 more
europepmc   +1 more source

Efficacy of Obinutuzumab for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome. [PDF]

Kidney Int Rep
Li Y, Hu H, Ai Y, Huo Q, Gong S, Yao M, Xin W, Zhu Y, Li S, Yao H, Cheng J, Huang Y.   +11 more
europepmc   +1 more source

Real-World Treatment Patterns and Safety Outcomes of Targeted Therapies in a Single-Center Chronic Lymphocytic Leukemia Cohort. [PDF]

Medicina (Kaunas)
Jeral Evinç S, Eyüpler Akmercan Ç, Ercan T, Arıkan F, Mengüç MU, Toptaş T, Atagündüz I, Tuğlular T, Yılmaz AF.   +8 more
europepmc   +1 more source

Corrigendum to "Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study" EClinicalMedicine. 2025 Jul 25:86:103383. [PDF]

EClinicalMedicine
Wróbel T, Kalicińska E, Zaucha JM, Morawska M, Giannopoulos K, Jamroziak K, Lech-Marańda E, Taszner M, Szeremet A, Małecki B, Druzd-Sitek A, Łojko-Dankowska A, Dytfeld D.   +12 more
europepmc   +1 more source